Chronic oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed a diet high in sucrose and saturated fat
暂无分享,去创建一个
S. Subramanian | R. Yeung | W. Ladiges | L. Goodspeed | K. O’Brien | M. Omer | L. D. den Hartigh | H. Kenerson | Shari Wang
[1] S. Kuang,et al. Adipocyte-specific DKO of Lkb1 and mTOR protects mice against HFD-induced obesity, but results in insulin resistance[S] , 2018, Journal of Lipid Research.
[2] D. Harrison,et al. Cardioprotective effects of dietary rapamycin on adult female C57BLKS/J‐Leprdb mice , 2018, Annals of the New York Academy of Sciences.
[3] S. Collins,et al. Cardiac natriuretic peptides promote adipose ‘browning’ through mTOR complex-1 , 2018, Molecular metabolism.
[4] D. Rader,et al. mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion , 2017, The Journal of clinical investigation.
[5] S. Subramanian,et al. Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice , 2017, PloS one.
[6] N. Câmara,et al. mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function. , 2017, Immunobiology.
[7] Wei Zhang,et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] D. Harrison,et al. Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes , 2016, Aging.
[9] S. Kuang,et al. Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice , 2016, Diabetologia.
[10] Kalyani V. P. Guntur,et al. Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning. , 2016, The Journal of clinical investigation.
[11] Dudley Lamming,et al. Rapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue , 2016, Diabetes.
[12] S. A. Arriola Apelo,et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system , 2015, Aging cell.
[13] Dudley Lamming,et al. Rapamycin-induced metabolic defects are reversible in both lean and obese mice , 2014, Aging.
[14] M. Westerterp,et al. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice , 2014, Diabetologia.
[15] P. Froguel,et al. Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice , 2014, PloS one.
[16] M. Blagosklonny,et al. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet , 2014, Aging cell.
[17] Z. D. Sharp,et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction , 2014, Aging cell.
[18] H. Fuchs,et al. Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.
[19] Yun Shi,et al. Rapamycin Modulates Markers of Mitochondrial Biogenesis and Fatty Acid Oxidation in the Adipose Tissue of db/db Mice. , 2013, Journal of biochemical and pharmacological research.
[20] J. Olefsky,et al. Liver-specific p70 S6 Kinase Depletion Protects against Hepatic Steatosis and Systemic Insulin Resistance* , 2012, The Journal of Biological Chemistry.
[21] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[22] Dudley Lamming,et al. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.
[23] V. Anisimov,et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice , 2011, Cell cycle.
[24] Y. Jan,et al. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity , 2011, Journal of Molecular Medicine.
[25] R. de Cabo,et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.
[26] D. Sabatini,et al. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. , 2010, Molecular cell.
[27] Jayanta Debnath,et al. Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.
[28] Y. Deshaies,et al. Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue , 2010, Diabetes.
[29] C. Glass,et al. Macrophages, inflammation, and insulin resistance. , 2010, Annual review of physiology.
[30] Janet M. Thornton,et al. Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.
[31] H. Hsu,et al. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. , 2009, Basic & clinical pharmacology & toxicology.
[32] Marco Pahor,et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.
[33] A. Thomson,et al. Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.
[34] Geng-Ruei Chang,et al. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. , 2009, Journal of pharmacological sciences.
[35] J. Auwerx,et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.
[36] Claudio R. Santos,et al. SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth , 2008, Cell metabolism.
[37] H. Meier‐Kriesche,et al. Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[38] A. Webster,et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.
[39] S. Subramanian,et al. Dietary Cholesterol Worsens Adipose Tissue Macrophage Accumulation and Atherosclerosis in Obese LDL Receptor–Deficient Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[40] Christophe Magnan,et al. mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes , 2008, Diabetes.
[41] J. Cruzado. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. , 2008, Transplantation reviews.
[42] V. Mootha,et al. mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.
[43] G. Thomas,et al. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. , 2007, Trends in molecular medicine.
[44] M. Roden,et al. The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man , 2007, Diabetes.
[45] C. Tsang,et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.
[46] J. Romijn,et al. Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice , 2006, Diabetologia.
[47] M. Fernández,et al. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. , 2006, Metabolism: clinical and experimental.
[48] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[49] D. Sabatini,et al. Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.
[50] S. di Paolo,et al. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.
[51] Peter Nowotny,et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. , 2005, Diabetes.
[52] A. Marette,et al. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. , 2005, Endocrinology.
[53] Johan Auwerx,et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.
[54] C. Ballantyne,et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200 , 2002, Journal of Lipid Research.
[55] R. Burcelin,et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.
[56] J. Sredy,et al. Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice , 1992, Clinical and experimental immunology.
[57] J. Folch,et al. A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.